Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Inspire Investing LLC

Inspire Investing LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 34.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,384 shares of the biopharmaceutical company’s stock after purchasing an additional 3,156 shares during the period. Inspire Investing LLC’s holdings in Agios Pharmaceuticals were worth $407,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the last quarter. CWM LLC grew its stake in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 1,836 shares during the period. Quest Partners LLC raised its holdings in Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth $146,000. Finally, XTX Topco Ltd purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $230,000.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $34.46 on Friday. The business’s 50-day moving average is $42.36 and its two-hundred day moving average is $44.79. The firm has a market capitalization of $1.97 billion, a PE ratio of 3.03 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a 12 month low of $21.66 and a 12 month high of $62.58.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on AGIO. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Raymond James restated an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.